Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses how Inlexzo and increasingly complex urologic cancer therapies are driving closer coordination between urology and oncology pharmacy.
Jennifer Griffin, PharmD, MS, discusses how pharmacists' accessibility and trust position them to fight vaccine misinformation and help close a coming gap in health care access as physician shortages loom.
The conversation centers on colorectal cancer screening, at-home COVID and flu testing, and fertility testing, with McPhillips and James stressing that pharmacists shouldn't shy away from uncomfortable conversations or treat self-tests as a substitute for further care.
Learn how pharmacists spot systemic mastocytosis sooner—using sensitive KIT testing, WHO/ICC criteria, and smarter referrals to improve outcomes.
Learn how pharmacists spot systemic mastocytosis sooner—using sensitive KIT testing, WHO/ICC criteria, and smarter referrals to improve outcomes.
Finally, Winter and Maroney synthesize the most critical practical lessons for pharmacy professionals and health care providers caring for patients with EDS in narcolepsy and OSA. They provide the essential roadmap pharmacists need to optimize outcomes for patients with EDS—from initial identification through long-term therapy management.
Winter explores how solriamfetol's emerging pipeline (ADHD, binge eating disorder, major depressive disorder, shift work disorder) may reshape the future of CNS pharmacology and the pharmacist's evolving role in this space.
Maroney outlines the key safety considerations pharmacists and clinicians should weigh when prescribing solriamfetol for EDS in narcolepsy or OSA. She highlights the drug's favorable interaction profile—since it isn't a substrate for major CYP enzymes, unlike modafinil, armodafinil, and pitolisant—making it a practical option for patients managing comorbidities on polypharmacy regimens.
Maroney discusses practical strategies for navigating coverage determinations and prior authorizations for patients prescribed solriamfetol. Current data show roughly 95% of commercially insured patients already have access to the drug, suggesting access barriers, while real, are often surmountable
Winter examines the TONES 5 randomized-withdrawal trial, discussing how sustained efficacy over 6 months factors into clinical decision-making and patient adherence in a chronic condition like EDS.
Winter breaks down the TONES clinical trial program, discussing ESS and Maintenance of Wakefulness Test end points. He covers how these benchmarks translate into what patients actually experience as functional improvements in their daily lives—helping pharmacists understand the real-world significance of the trial data.
Winter explains solriamfetol's distinct pharmacological profile as a dopamine-norepinephrine reuptake inhibitor—the first and only agent in its class approved specifically for EDS—and discusses why this mechanism matters clinically compared to other available wakefulness-promoting options.
Winter opens the discussion by highlighting that millions of Americans with narcolepsy and OSA suffer from undertreated EDS. He sets the stage for understanding the unmet need that solriamfetol addresses.
Zahra Mahmoudjafari expressed optimism about the remarkable evolution of multiple myeloma management over her career while acknowledging the significant responsibility that accompanies the expanding therapeutic landscape, emphasizing the need for operational infrastructure that ensures appropriate access, continued advocacy around Risk Evaluation and Mitigation Strategy (REMS) programs, and strong cross-specialty partnerships such as those with ophthalmology that are critical to safely delivering agents like belantamab mafodotin.
Zahra Mahmoudjafari outlined best practices for pharmacist-led patient education across all three BCMA-directed therapy classes, emphasizing the importance of tailored, proactive counseling that accounts for the unique toxicity profiles of each agent, including cytokine release syndrome (CRS) and neurotoxicity risk with CAR T-Cell therapies and bispecific antibodies, ocular symptoms such as blurred vision and dry eye with belantamab mafodotin, and infection risk across all modalities, while also stressing the critical role of care partners in recognizing and escalating adverse events early.
Winter opens the discussion by highlighting that millions of Americans with narcolepsy and OSA suffer from undertreated EDS. He sets the stage for understanding the unmet need that solriamfetol addresses.
Andrew Bzowyckyj, PharmD, explains how the CKM framework turns albuminuria, ejection fraction, and inflammation into patient-specific risk stratification.
This episode, titled 'Availability, Patient Preference, and Linvoseltamab: What Pharmacists Need to Know About the Evolving Bispecific Landscape,' features oncology pharmacists discussing the following critical questions:
In 'Patient Selection and Line-of-Therapy Navigation: Practical Insights for a Complex Myeloma Treatment Landscape,' our panel of experts delve into the following critical questions:
From double-dipping GLP-1s to off-label pioglitazone, Susan Cornell, PharmD, breaks down where the metabolic dysfunction-associated steatotic liver disease (MASLD) drug evidence stands today.
James and McPhillips unpack the everyday barriers that keep patients from addressing health concerns and make the case for at-home testing as a way around them, then turn to how pharmacists can improve their counseling once a patient shows up with results in hand.
Al-Ola Abdallah outlined the key adverse events associated with bispecific antibodies, noting that while CRS occurs in over 70% of patients, the majority of cases are grade 1 or 2 and therefore manageable in outpatient settings with appropriate infrastructure, while ICANS is less commonly observed at severe grades compared with CAR T-Cell therapy.
Zahra Mahmoudjafari explained that REMS programs are a Food and Drug Administration (FDA) mechanism designed to ensure that the safety risks associated with specific therapies are clearly communicated to prescribers, healthcare facilities, pharmacies, and patients, noting that each REMS program is unique and that BCMA-directed therapies currently carry REMS requirements for bispecific antibodies due to cytokine release syndrome (CRS) and neurotoxicity risks, and for belantamab mafodotin due to ocular toxicity, while the REMS programs previously required for CAR T-Cell therapies were recently removed.
Finally, Zepcan and Ali reflect on the single most important lessons for pharmacists new to menin inhibitor therapy and share what they wish they'd known on day one.
In this episode, 'The Long-Term Infection Risk: How Pharmacists Are Approaching Prophylaxis and Monitoring in Bispecific Myeloma Care,' the oncology pharmacists explore the following questions:
In this episode, 'From Treatment to Prevention: How Pharmacists Are Refining CRS Management for Bispecific Antibody Therapy,' the oncology pharmacists explore the following questions:
Jerry P. Abraham, MD, MPH, CMQ, discusses why COVID-19 prevention strategies, including ensitrelvir for postexposure prophylaxis, remain essential for protecting vulnerable patients amid persistent summer transmission.
Jerry P. Abraham, MD, MPH, CMQ, discusses how ensitrelvir's new post-exposure prophylaxis indication gives pharmacists a critical 72-hour window to help prevent COVID-19 in high-risk patients.
Learn how AIMS scoring, video tracking, and team-based follow-up boost tardive dyskinesia detection and VMAT2 treatment persistence.
Boost tardive dyskinesia care with VMAT2 inhibitor education, social media stories, and pharmacist–prescriber teamwork for monitoring and access.
